| Not Yet Recruiting | A Study to Learn More About Tukysa Once it is Out in the Korean Market NCT06873191 | Pfizer | — |
| Not Yet Recruiting | Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Interventi NCT07519200 | Dana-Farber Cancer Institute | N/A |
| Not Yet Recruiting | Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice NCT06882499 | Peter MacCallum Cancer Centre, Australia | N/A |
| Not Yet Recruiting | Pulsed Electric Field Ablation for Metastatic Breast Cancer NCT07487844 | University of California, San Francisco | N/A |
| Not Yet Recruiting | Generative AI Patient Education Module for Breast Oncology NCT07512271 | University of California, San Francisco | N/A |
| Suspended | Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC) NCT06214793 | Megan Kruse, MD | Phase 2 |
| Recruiting | A Study of HLD-0117 in Patients With Metastatic Breast Cancer NCT07524855 | Halda Therapeutics OpCo, Inc. | Phase 1 |
| Not Yet Recruiting | Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer NCT07179809 | M.D. Anderson Cancer Center | N/A |
| Recruiting | Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer NCT07408089 | Boundless Bio, Inc. | Phase 1 |
| Recruiting | Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution NCT07084571 | Royal Marsden NHS Foundation Trust | — |
| Recruiting | Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies NCT07340541 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Recruiting | Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of B NCT07233928 | Institut Claudius Regaud | N/A |
| Recruiting | Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Can NCT07252726 | Ottawa Hospital Research Institute | Phase 4 |
| Not Yet Recruiting | A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer NCT07227831 | Barbara Ann Karmanos Cancer Institute | N/A |
| Recruiting | A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3C NCT07347600 | Hoffmann-La Roche | — |
| Recruiting | PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) NCT07222215 | Kristina A. Fanucci | Phase 2 |
| Not Yet Recruiting | RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure NCT07366840 | Fudan University | Phase 2 / Phase 3 |
| Not Yet Recruiting | Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer NCT07368543 | Fudan University | Phase 2 |
| Withdrawn | A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-lo NCT06585969 | Danish Breast Cancer Cooperative Group | Phase 3 |
| Not Yet Recruiting | JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer NCT07336771 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise NCT07313306 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Recruiting | Assessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Pa NCT06962163 | Institut Cancerologie de l'Ouest | N/A |
| Recruiting | PTEN and Organ-Specific microRNAs in Metastatic Breast Cancer NCT07297134 | Atlas University | — |
| Recruiting | Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Stan NCT07281833 | West German Study Group | Phase 3 |
| Recruiting | ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor an NCT07198724 | Sarah Sammons, MD | Phase 1 / Phase 2 |
| Recruiting | Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu NCT07203378 | University of Utah | Phase 2 |
| Recruiting | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer NCT07085767 | Olema Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer NCT06774027 | University of California, San Francisco | — |
| Recruiting | A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metast NCT07081555 | Affibody | Phase 1 |
| Recruiting | Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer NCT06525766 | Mayo Clinic | Phase 2 |
| Recruiting | Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer NCT06795529 | Massachusetts General Hospital | N/A |
| Active Not Recruiting | Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United Sta NCT07342309 | Boehringer Ingelheim | — |
| Recruiting | A Study of Surgery and Radiotherapy in People With Breast Cancer NCT07053085 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Not Yet Recruiting | PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer NCT07130344 | Centre Paul Strauss | N/A |
| Not Yet Recruiting | Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer NCT06835400 | Health Hope Pharma | Phase 3 |
| Recruiting | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Met NCT06982521 | Relay Therapeutics, Inc. | Phase 3 |
| Recruiting | Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breas NCT06904625 | Institut Claudius Regaud | N/A |
| Recruiting | Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer NCT07049133 | European Institute of Oncology | — |
| Completed | Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant NCT07008963 | AstraZeneca | — |
| Recruiting | A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Ca NCT07024173 | Shandong Suncadia Medicine Co., Ltd. | Phase 3 |
| Recruiting | A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, NCT07071337 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced B NCT07008976 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 3 |
| Not Yet Recruiting | Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer NCT07019337 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy NCT06994377 | European Institute of Oncology | — |
| Recruiting | A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC NCT07002177 | Forward Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic B NCT06991946 | SOLTI Breast Cancer Research Group | — |
| Withdrawn | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Vari NCT04889495 | Pfizer | — |
| Recruiting | A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combinati NCT06827236 | BioNTech SE | Phase 1 / Phase 2 |
| Recruiting | FDG-PET/CT vs. CT for Monitoring Metastatic Breast Cancer NCT06877949 | Odense University Hospital | N/A |
| Not Yet Recruiting | Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positiv NCT06797622 | Fudan University | Phase 2 |
| Recruiting | Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer NCT06105684 | University of Alabama at Birmingham | Phase 2 |
| Recruiting | BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growt NCT06756932 | BeOne Medicines | Phase 1 |
| Recruiting | Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests. NCT06450314 | UNICANCER | Phase 2 |
| Recruiting | HER-2 B Cell Peptide Vaccine NCT06414733 | Pravin T.P Kaumaya | Phase 1 |
| Recruiting | Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer NCT06900647 | Sun Yat-sen University | Phase 1 |
| Recruiting | Promoting Resilience in Women With Breast Cancer (PRISM -MBC) NCT06855654 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Recruiting | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors NCT06784193 | Olema Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid (AVATAR) NCT06459791 | Institut Curie | N/A |
| Not Yet Recruiting | JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC NCT06731153 | Fudan University | Phase 2 |
| Recruiting | Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-0 NCT06428396 | Merck Sharp & Dohme LLC | Phase 2 |
| Recruiting | A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurre NCT06369285 | Puma Biotechnology, Inc. | Phase 2 |
| Recruiting | A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer NCT06678269 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors NCT06625775 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1 |
| Recruiting | The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study NCT06377852 | American Society of Clinical Oncology | Phase 3 |
| Recruiting | TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd NCT06533826 | Ana C Garrido-Castro, MD | Phase 2 |
| Recruiting | Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer NCT06649331 | Fudan University | Phase 2 |
| Recruiting | The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positi NCT06641544 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 4 |
| Recruiting | Mechanisms of Response and Resistance to Innovative Treatments in Patients With Locally Advanced or Metastatic NCT07066917 | Hellenic Cooperative Oncology Group | — |
| Recruiting | A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors NCT06533332 | EtiraRx Australia Pty Ltd | Phase 1 |
| Recruiting | BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Bre NCT05977036 | Washington University School of Medicine | N/A |
| Recruiting | Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC NCT06793553 | Japan Breast Cancer Research Group | Phase 2 |
| Recruiting | HER2 Targeted Molecular Imaging in mBC Using 68Ga-ABS011 NCT06369831 | Abscint NV/SA | Phase 2 |
| Recruiting | The COMPASSION Study NCT06507930 | Dana-Farber Cancer Institute | N/A |
| Not Yet Recruiting | STereotactic Body Radiotherapy (SBRT) for Oligoprogressive Breast Cancer NCT06489821 | Juravinski Cancer Center | N/A |
| Not Yet Recruiting | Collaborative cOMMUNIty Care for Metastatic breAsT cancEr Patients in inDonesia (Communicated) NCT06517992 | Gadjah Mada University | N/A |
| Recruiting | Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer NCT06409390 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer NCT06557148 | Memorial Sloan Kettering Cancer Center | — |
| Active Not Recruiting | A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab a NCT07386938 | R-Pharm | Phase 3 |
| Active Not Recruiting | Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer NCT06590857 | RayzeBio, Inc. | Phase 1 / Phase 2 |
| Recruiting | Estradiol Plus Olaparib for Breast Cancer (PHOEBE) NCT05900895 | Mary D Chamberlin | Phase 1 |
| Recruiting | A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer NCT06383767 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers NCT05846789 | Kathy Miller | Phase 2 |
| Not Yet Recruiting | Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatm NCT06154590 | DR. DIANE CHISESI NFS. MD. PHD. | — |
| Not Yet Recruiting | Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients. NCT06338644 | Helwan University | — |
| Completed | Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer NCT06408038 | Institut Claudius Regaud | N/A |
| Recruiting | A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of A NCT06598046 | Henan Cancer Hospital | Phase 2 |
| Recruiting | Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC NCT06263543 | Reshma L. Mahtani, D.O. | Phase 2 |
| Recruiting | Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer. NCT06417801 | AstraZeneca | — |
| Recruiting | NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial NCT06342037 | The Netherlands Cancer Institute | Phase 2 |
| Active Not Recruiting | Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer NCT07371910 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 |
| Active Not Recruiting | T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases NCT06048718 | MedSIR | Phase 2 |
| Recruiting | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatm NCT06324357 | Boehringer Ingelheim | Phase 1 / Phase 2 |
| Recruiting | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors NCT06157892 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Recruiting | Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer NCT06405828 | Icahn School of Medicine at Mount Sinai | N/A |
| Recruiting | DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients NCT06388122 | Mayo Clinic | — |
| Completed | A Study of Real-world Outcomes Among Patients Treated With Ribociclib NCT07148505 | Novartis Pharmaceuticals | — |
| Completed | HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada NCT06386263 | AstraZeneca | — |
| Active Not Recruiting | BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and O NCT06253195 | BeiGene | Phase 1 |
| Recruiting | Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Old NCT06044623 | Region Örebro County | Phase 3 |
| Not Yet Recruiting | A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer NCT06023277 | Jacinto Convit World Organization Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2 NCT06308939 | Zhejiang Cancer Hospital | Phase 2 |
| Unknown | Discovering Factors in Metastatic Breast Cancer Patients' Clinical Trial Experiences NCT05760183 | Power Life Sciences Inc. | — |
| Completed | The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity NCT06343987 | Aarhus University Hospital | N/A |
| Withdrawn | INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 NCT05703555 | Erasmus Medical Center | Phase 2 |
| Recruiting | A Study of Pembrolizumab and Cryoablation in People With Breast Cancer NCT06246968 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness NCT05968144 | University of Maryland, Baltimore | Phase 1 / Phase 2 |
| Unknown | HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer NCT06328387 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metasta NCT06018337 | DualityBio Inc. | Phase 3 |
| Withdrawn | Study of OB-002 in Patients With Refractory Metastatic Cancer NCT05940844 | Orion Biotechnology Polska Sp. z o.o. | Phase 1 |
| Recruiting | A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer NCT06110793 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry) NCT05964504 | University of California, San Francisco | — |
| Completed | Doxil/Caelyx BE Study NCT05567601 | Baxter Healthcare Corporation | Phase 1 |
| Recruiting | Definitive Radiation for High-Risk Spine Metastases NCT06165419 | Stony Brook University | Phase 2 |
| Recruiting | Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. NCT06072612 | BriaCell Therapeutics Corporation | Phase 3 |
| Recruiting | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Soli NCT06120283 | BeOne Medicines | Phase 1 |
| Unknown | Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemothe NCT06151249 | Chung Shan Medical University | Phase 2 |
| Terminated | Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer NCT05954143 | Bolt Biotherapeutics, Inc. | Phase 2 |
| Active Not Recruiting | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease NCT05865990 | MedSIR | Phase 2 |
| Recruiting | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer NCT06016738 | Olema Pharmaceuticals, Inc. | Phase 3 |
| Completed | A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adu NCT05963984 | Carrick Therapeutics Limited | Phase 2 |
| Active Not Recruiting | Assessing the Time Demands of Cancer NCT05708703 | Masonic Cancer Center, University of Minnesota | — |
| Completed | CALM: Managing Distress in Malignant Brain Cancer NCT06180460 | Virginia Commonwealth University | N/A |
| Recruiting | Metastasis-directed Therapy for Oligometastases of Breast Cancer NCT06135714 | Tokyo Medical and Dental University | Phase 3 |
| Unknown | The Impact of Adverse Events, Produced by Antibodies Conjugates, on Quality of Life in Patients With Metastati NCT06106711 | Centro di Riferimento Oncologico - Aviano | — |
| Not Yet Recruiting | Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients NCT06076772 | Assiut University | — |
| Recruiting | Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer NCT06081959 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Lo NCT05696626 | LeonaBio | Phase 3 |
| Withdrawn | A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer NCT06145399 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Recruiting | DESTINY Breast Respond HER2-low Europe NCT05945732 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | — |
| Recruiting | Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy NCT06055881 | Mayo Clinic | N/A |
| Recruiting | Using a Blood Test to Monitor Metastatic Breast Cancer Treatment NCT05804578 | Dr. Christopher Mueller | — |
| Recruiting | A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metasta NCT06099769 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative NCT05963997 | Carrick Therapeutics Limited | Phase 1 / Phase 2 |
| Active Not Recruiting | Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpeli NCT06083038 | HealthPartners Institute | — |
| Recruiting | Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative NCT05552001 | UNICANCER | Phase 3 |
| Recruiting | Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metas NCT06062498 | Northwestern University | Phase 2 |
| Terminated | Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pert NCT05744375 | Spanish Breast Cancer Research Group | Phase 2 |
| Recruiting | Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort NCT05693766 | Sonya Reid | Phase 2 |
| Recruiting | Metastases Directed Therapy for Oligometastatic Breast Cancer NCT06144346 | National Cancer Institute, Egypt | N/A |
| Recruiting | Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Lu NCT05954442 | Fudan University | Phase 3 |
| Recruiting | A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. NCT06064812 | Forward Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combina NCT05894239 | Hoffmann-La Roche | Phase 3 |
| Withdrawn | Fulvestrant + Neratinib In Breast Cancer NCT04901299 | Massachusetts General Hospital | Phase 2 |
| Unknown | 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study NCT05955833 | Amsterdam UMC, location VUmc | Phase 1 |
| Active Not Recruiting | Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metasta NCT05826964 | University of Miami | Phase 2 |
| Completed | Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB NCT07416409 | Deraya University | — |
| Withdrawn | A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP3 NCT04252768 | Immutep S.A.S. | Phase 1 |
| Recruiting | Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hor NCT05816655 | Korea University Guro Hospital | Phase 2 |
| Active Not Recruiting | PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin NCT05810870 | MedSIR | Phase 2 |
| Active Not Recruiting | ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic NCT05596409 | Stemline Therapeutics, Inc. | Phase 2 |
| Recruiting | Prospective Observational Study on Outcome of High-precision Hypo-fractionated Radiotherapy in Metastatic Brea NCT05907681 | Samsung Medical Center | — |
| Active Not Recruiting | A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain NCT05892068 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER) NCT05716516 | Dartmouth-Hitchcock Medical Center | Phase 2 |
| Completed | Enhancing Therapy Adherence Among Metastatic Breast Cancer Patients NCT06161181 | European Institute of Oncology | N/A |
| Active Not Recruiting | STOP-HER2: Stopping Trastuzumab in HER2+ MBC NCT05721248 | Dana-Farber Cancer Institute | Phase 2 |
| Unknown | Study of TFX06 in Women With Advanced Breast Cancer. NCT05927779 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Brea NCT06202261 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Measuring Oncological Value of Exercise and Statin NCT05796973 | Tampere University Hospital | Phase 3 |
| Recruiting | Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases NCT05769010 | Henan Cancer Hospital | Phase 2 |
| Completed | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors NCT05759949 | Relay Therapeutics, Inc. | Phase 1 |
| Recruiting | Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients NCT05732051 | University Hospital, Akershus | Phase 2 |
| Withdrawn | Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Brea NCT05079360 | Veru Inc. | Phase 2 |
| Completed | Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokineti NCT06074757 | Kashiv BioSciences, LLC | Phase 1 |
| Recruiting | PRE-I-SPY Phase I/Ib Oncology Platform Program NCT05868226 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Unknown | Olaparib Maintenance Therapy in Metastatic Breast Cancer NCT05629429 | National Taiwan University Hospital | Phase 2 |
| Unknown | Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy NCT05919212 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Recruiting | Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors NCT05544240 | Williams Cancer Foundation | Phase 1 |
| Recruiting | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participant NCT05563220 | Stemline Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC NCT05720260 | National Taiwan University Hospital | Phase 2 |
| Recruiting | Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) NCT05660083 | The Methodist Hospital Research Institute | Phase 2 |
| Recruiting | Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic A NCT05573126 | Ellipses Pharma | Phase 1 / Phase 2 |
| Terminated | Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients NCT05068726 | GE Healthcare | — |
| Recruiting | Adaptation of a Values Assessment Tool NCT07068477 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Recruiting | Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA I NCT07073755 | Hunan Cancer Hospital | — |
| Active Not Recruiting | Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Su NCT04920708 | Royal Marsden NHS Foundation Trust | Phase 2 |
| Recruiting | A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone i NCT05753657 | Rambam Health Care Campus | EARLY_Phase 1 |
| Active Not Recruiting | ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC) NCT05662345 | Menarini Silicon Biosystems, INC | — |
| Recruiting | The Impact of Radiotherapy on Oligometastatic Cancer NCT05933876 | Institut Investigacio Sanitaria Pere Virgili | — |
| Unknown | Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced NCT05577923 | Fudan University | Phase 2 |
| Recruiting | Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer NCT03824145 | Medical College of Wisconsin | N/A |
| Recruiting | Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns NCT06551220 | Sun Yat-sen University | — |
| Unknown | A Qualitative Study on Treatment Adherence in Patients With Metastatic Breast Cancer NCT06343181 | European Institute of Oncology | — |
| Active Not Recruiting | Onvansertib + Paclitaxel In TNBC NCT05383196 | Antonio Giordano, MD | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadil NCT05283837 | Zydus Lifesciences Limited | Phase 3 |
| Completed | Metastatic Breast Cancer-Specific Prognostic Tool NCT05574478 | UNC Lineberger Comprehensive Cancer Center | — |
| Recruiting | A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Trea NCT05534438 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Withdrawn | Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC NCT05191004 | Nuvation Bio Inc. | Phase 1 / Phase 2 |
| Recruiting | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmocicli NCT05508906 | Olema Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer NCT05524584 | University of California, Irvine | Phase 2 |
| Recruiting | Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast NCT05455619 | SynDevRx, Inc. | Phase 1 / Phase 2 |
| Terminated | Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer NCT05243641 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breas NCT06619704 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer NCT05463601 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Not Yet Recruiting | Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy NCT05285332 | Changhai Hospital | N/A |
| Completed | Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study) NCT06525675 | MedSIR | — |
| Recruiting | Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Spec NCT05440929 | UNC Lineberger Comprehensive Cancer Center | — |
| Active Not Recruiting | Roll-over Study to Allow Continued Access to Ribociclib NCT05161195 | Novartis Pharmaceuticals | Phase 4 |
| Withdrawn | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy NCT04941365 | Institut du Cancer de Montpellier - Val d'Aurelle | N/A |
| Recruiting | Comprehensive Outcomes for After Cancer Health NCT05349227 | Pack Health | N/A |
| Completed | Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locall NCT05303129 | Centre Francois Baclesse | N/A |
| Withdrawn | Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer NCT05227131 | MedSIR | Phase 2 |
| Recruiting | CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer NCT05029999 | University of Texas Southwestern Medical Center | Phase 1 |
| Terminated | Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast NCT05065411 | Veru Inc. | Phase 3 |
| Unknown | A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of NCT05331326 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With Hi NCT03492918 | Yonsei University | Phase 2 |
| Active Not Recruiting | Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype NCT05207709 | SOLTI Breast Cancer Research Group | Phase 3 |
| Completed | Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast NCT05340413 | SOLTI Breast Cancer Research Group | Phase 2 |
| Recruiting | Preoperative Radiotherapy and Systemic Therapy Following Surgery in 'de Novo' Metastatic Breast Cancer NCT05334459 | Ankara Oncology Research and Training Hospital | — |
| Completed | D4 Choline Breast PET/CT NCT04276272 | Imperial College London | — |
| Completed | Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to H NCT05217381 | MedSIR | — |
| Active Not Recruiting | Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer NCT05486182 | GE Healthcare | Phase 4 |
| Completed | European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies NCT05043506 | Pfizer | — |
| Recruiting | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzu NCT05143970 | Institut Paoli-Calmettes | Phase 1 |
| Completed | Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Canc NCT04983238 | Byondis B.V. | Phase 1 / Phase 2 |
| Withdrawn | Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC NCT05233696 | University of Colorado, Denver | Phase 2 |
| Completed | Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as NCT05132101 | Pfizer | — |
| Completed | Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2 NCT05141708 | Pfizer | — |
| Unknown | Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period NCT05135104 | Asociatia Oncohelp - Centrul de Oncologie Oncohelp | — |
| Terminated | Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Ca NCT05176080 | Henan Cancer Hospital | Phase 1 / Phase 2 |
| Recruiting | First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advance NCT05216432 | Relay Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer NCT06570031 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer NCT05086731 | Emory University | N/A |
| Completed | Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer NCT05021900 | Rhizen Pharmaceuticals SA | Phase 2 |
| Terminated | Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer NCT04869943 | Veru Inc. | Phase 3 |
| Active Not Recruiting | Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer NCT05090358 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Scalp Cooling in MBC NCT04986579 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors NCT05002868 | Rhizen Pharmaceuticals SA | Phase 1 |
| Terminated | Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer NCT04720664 | Georgetown University | Phase 2 |
| Unknown | Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab NCT05346861 | Fudan University | Phase 3 |
| Completed | A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer NCT05054374 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Unknown | BRaziLian outcomE for metAStatic breasT Cancer NCT05559528 | Hospital do Coracao | — |
| Withdrawn | A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer NCT04872608 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer NCT04990921 | University of Louisville | Phase 2 |
| Completed | Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor NCT05361655 | Pfizer | — |
| Unknown | Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Can NCT05025735 | Saint Luke's Health System | Phase 2 |
| Unknown | Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients Wi NCT04963595 | Zhiyong Yu | Phase 2 |
| Withdrawn | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With NCT04602117 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Unknown | ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study) NCT04669587 | EnhancedBio USA Inc. | Phase 1 / Phase 2 |
| Recruiting | Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients NCT04608357 | Sunnybrook Health Sciences Centre | — |
| Completed | Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palboci NCT05012644 | Pfizer | — |
| Completed | Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC NCT04937660 | Pfizer | — |
| Completed | Implication of CCR4-NOT Complex Subunit 7 Expression in Natural Killer Cell Resistance in Metastatic Breast Ca NCT06320392 | Ain Shams University | — |
| Unknown | A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic NCT04924699 | Shanghai Miracogen Inc. | Phase 2 / Phase 3 |
| Completed | A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) NCT04834778 | HiberCell, Inc. | Phase 1 |
| Recruiting | A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer NCT04872166 | Edgewood Oncology Inc. | Phase 1 |
| Terminated | A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants W NCT04740918 | Hoffmann-La Roche | Phase 3 |
| Unknown | A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer. NCT04733417 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer NCT04573231 | University of Wisconsin, Madison | Phase 2 |
| Active Not Recruiting | Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer NCT04370522 | Spanish Breast Cancer Research Group | — |
| Completed | Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unr NCT04857619 | AstraZeneca | — |
| Recruiting | Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer NCT04965766 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Terminated | BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) NCT04296942 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response NCT04315233 | University of Utah | Phase 1 |
| Completed | A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer NCT04699630 | SCRI Development Innovations, LLC | Phase 2 |
| Recruiting | A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Tripl NCT04683679 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus NCT04734262 | Fudan University | Phase 2 |
| Unknown | Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer NCT05302778 | University of Milano Bicocca | — |
| Completed | Real-World Data on Clinical Characteristics, Demographics, and Outcomes of Patients With Metastatic Breast Can NCT04770129 | Turkish Oncology Group | — |
| Completed | Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Bre NCT04495309 | University Hospital Schleswig-Holstein | N/A |
| Completed | Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prost NCT04703920 | University of Michigan Rogel Cancer Center | Phase 1 |
| Terminated | Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. NCT04796324 | Allarity Therapeutics | Phase 2 |
| Unknown | Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cance NCT03749850 | UMC Utrecht | Phase 1 |
| Completed | Nurse AMIE for Echo Show: Randomized Control Trial NCT04673019 | Milton S. Hershey Medical Center | N/A |
| Completed | Feasibility of Fasting & Exercise in Pts With HR+ MBC NCT04708860 | Dana-Farber Cancer Institute | N/A |
| Unknown | Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC NCT05131841 | Zhejiang Cancer Hospital | Phase 4 |
| Active Not Recruiting | Couples' QOL in Metastatic Breast Cancer NCT05636943 | Fox Chase Cancer Center | N/A |
| Unknown | Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC NCT04609540 | Shandong Cancer Hospital and Institute | — |
| Active Not Recruiting | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer NCT04538742 | AstraZeneca | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer NCT04556773 | AstraZeneca | Phase 1 |
| Terminated | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors NCT04541225 | Nuvation Bio Inc. | Phase 1 |
| Completed | A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbocicl NCT04671615 | Pfizer | — |
| Active Not Recruiting | Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) NCT04639986 | Gilead Sciences | Phase 3 |
| Active Not Recruiting | Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast C NCT04497285 | SOLTI Breast Cancer Research Group | — |
| Completed | HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Br NCT03685331 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer NCT05206656 | Hunan Cancer Hospital | Phase 2 |
| Completed | First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC NCT04408118 | MedSIR | Phase 2 |
| Completed | Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an NCT04432454 | Sermonix Pharmaceuticals Inc. | Phase 2 |
| Active Not Recruiting | Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC NCT04448886 | Ana C Garrido-Castro, MD | Phase 2 |
| Active Not Recruiting | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NCT04140526 | OncoC4, Inc. | Phase 1 / Phase 2 |
| Completed | Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/ NCT04352777 | Duke University | Phase 2 |
| Terminated | Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer NCT03982004 | Washington University School of Medicine | Phase 1 |
| Recruiting | To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer NCT04660435 | Fondazione Sandro Pitigliani | — |
| Recruiting | PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer NCT04360941 | Royal Marsden NHS Foundation Trust | Phase 1 |
| Terminated | Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor P NCT04251169 | SOLTI Breast Cancer Research Group | Phase 2 |
| Unknown | Atezolizumab Plus CArboplatin Plus Nab-paclitaxel NCT05266937 | Consorzio Oncotech | Phase 2 |
| Active Not Recruiting | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors NCT04478279 | Sapience Therapeutics | Phase 1 / Phase 2 |
| Unknown | A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer NCT04354233 | Centre Leon Berard | N/A |
| Completed | Living Better With Advanced Breast Cancer: Feasibility Evaluation of an Online Supportive Intervention. NCT04173897 | University of Leeds | N/A |
| Unknown | Feasibility of Integrating the Outcomes4Me Smartphone Navigation Application Into the Care Management of Breas NCT04262518 | Outcomes4Me | N/A |
| Completed | Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metasta NCT04367090 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs NCT05153135 | Novartis Pharmaceuticals | — |
| Withdrawn | To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With L NCT04332549 | Sun Pharma Advanced Research Company Limited | Phase 1 |
| Unknown | ImmunoBreast - A Phase Ib Study NCT04609215 | Henrik Ditzel | Phase 1 / Phase 2 |
| Completed | A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/ NCT05141240 | Novartis Pharmaceuticals | — |
| Completed | Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastat NCT04134884 | Kathy Miller | Phase 1 |
| Unknown | Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer NCT04293276 | Henan Cancer Hospital | Phase 2 |
| Unknown | Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelb NCT04389073 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study) NCT04571437 | Cairo University | Phase 2 |
| Unknown | Implementing Patients´ Competence in Oral Breast Cancer Therapy NCT04030728 | Onco Medical Consult GmbH | — |
| Completed | Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients NCT04253561 | SOLTI Breast Cancer Research Group | Phase 1 |